New diabetes pill HDM1002 enters final testing phase

NCT ID NCT07193459

Recruiting now Disease control Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new oral medication, HDM1002, in 360 adults with type 2 diabetes whose blood sugar is not well controlled by diet and exercise alone. Participants will take either a low or high dose of HDM1002 or a placebo daily for 40 weeks. The main goal is to see if the drug lowers blood sugar levels (HbA1c) more than placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HDM1002 tablets
What this could lead to: If successful, HDM1002 could offer a new oral medication option to help control blood sugar and weight in people with type 2 diabetes.
What could go wrong: This is a relatively early Phase 3 trial, so the drug may not prove effective or safe compared to placebo. Side effects are possible, and results may not apply to all diabetes patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES

Contacts and locations

Locations

Peking University People's Hospital
RECRUITING

Beijing, Beijing Municipality, 100000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.